Key result
High antipsychotic adherence is linked to ~8% lower overall CVD/CEV risk, despite subgroup-specific harms.
Why the study?
This study aimed to investigate the effect of antipsychotic agents on cardiovascular and cerebrovascular diseases and mortality risks in community-dwelling older adults.
Does high adherence (≥60%) compared to low adherence (<60%) to typical and atypical antipsychotic agents increase the risk of incident cardiovascular and cerebrovascular diseases (CAD, MI, or stroke) and mortality in community-dwelling older adults?
Cohort (n=42,650)
Yes
Does high adherence (≥60%) compared to low adherence (<60%) to typical and atypical antipsychotic agents increase the risk of incident cardiovascular and cerebrovascular diseases (CAD, MI, or stroke) and mortality in community-dwelling older adults?
In community-dwelling older adults, high adherence to antipsychotics was not associated with an overall increase in cardiovascular/cerebrovascular risk except in specific sub-populations (atypical antipsychotics in schizophrenia and typical antipsychotics in dementia), whereas typical antipsychotics substantially increased mortality risk by 2- to 3-fold in a dose-dependent manner.
Answers are grounded in this paper and cite their sources.
May warrant mortality caution with typical antipsychotics in older adults; leaves open net cardiovascular effects in schizophrenia and dementia subgroups.
This study aims to investigate the effect of antipsychotic agents on cardiovascular and cerebrovascular diseases (CVD/CEV) and mortality risks in the older population living in a community. A cohort of 42,650 new users of antipsychotic agents was built using Quebec healthcare databases (1998-2011). The outcomes were CVD/CEV and mortality incidence in 5 years of follow-up in the total cohort, sub-cohort of patients with no schizophrenia/dementia, sub-cohort with schizophrenia, and sub-cohort with dementia. Comparisons were made between the new users who continued the treatment (adherent level ≥ 60%) vs. those ceasing treatment (adherence level < 60%) using inverse probability of treatment weighting and Cox models. Comparing high adherence vs. low levels, CVD/CEV risk was increased by 36% in the sub-cohort with schizophrenia for atypical antipsychotic users and by 25% in the sub-cohort with dementia for typical antipsychotic users. An increasing mortality risk of 2- to 3-fold was linked with the typical antipsychotic use in all cohorts except the sub-cohort with schizophrenia; in addition, mortality risk is linked with the use of high vs. low doses. Antipsychotics were not linked with CVD/CEV risk, except for atypical antipsychotics in patients with schizophrenia and typical antipsychotics in patients with dementia. The mortality risk was linked with the use of typical antipsychotics and the dose used.
No takes yet. Share an insight, caveat, or question.
Perreault et al. (2024) conducted a cohort in Community-dwelling older adults initiating antipsychotic agents (including sub-cohorts with schizophrenia, dementia, or neither) (n=42,650). High adherence to antipsychotic agents (medication possession ratio ≥60%) vs. Low adherence / cessation of antipsychotic agents (medication possession ratio <60%) was evaluated on Incident cardiovascular and cerebrovascular diseases (CVD/CEV: composite of new diagnosis of CAD, MI, or stroke) in the total cohort over 5 years (HR 0.92, 95% CI 0.89-0.96). High antipsychotic adherence was associated with lower overall CVD/CEV risk, but increased CVD/CEV in schizophrenia/dementia subgroups and a 2.49- to 3.55-fold mortality risk with typical agents.
Synapse has enriched 10 related papers. Consider them for comparative context: